LENZ LENZ Therapeutics, Inc. | US52635N1037
Company Profile
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Latest News
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
Zacks • 07/22/2026
California Department of Pesticide Regulation Confirms Licensed Pest Control Operators May Use TerraTrap for Ground Squirrel Control
GlobeNewswire • 07/23/2026
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Zacks • 07/23/2026
TerraTrap Expands Across California Agriculture Five Months After World Ag Expo Top-10 Win
GlobeNewswire • 07/22/2026
Buying Brewton Land Explained in HelloNation Featuring Real Estate Expert Melissa McMillan
PR Newswire • 07/17/2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.lenz-tx.com |
| Audit Risk | 6 |
| Board Risk | 7 |
| Overall Risk | 8 |
| Market Cap | 171.82M |
| Forward P/E | -1.56 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -3.64 |
| Forward EPS | -3.51 |
| Book Value | 7.86 |
| Price-to-Book | 0.7 |
| Enterprise-to-Revenue | -4.09 |
| Enterprise-to-EBITDA | 0.73 |
| Short Ratio | 11.56 |
| Dividend Date | 03/21/2024 |
| Earnings Date | 07/29/2026 |
| Earnings Call Date | 05/11/2026 |
| Earnings Average | -1.07 |
| Earnings Low | -1.37 |
| Earnings High | -0.53 |
| Revenue Average | 2.38M |
| Revenue Low | 1.60M |
| Revenue High | 3.30M |